Clinical management of amyloid cardiomyopathy
Clinical management of amyloid cardiomyopathy
复制标题
淀粉样心肌病的临床治疗
DOI：
10.1007/s10741-021-10159-w
复制
发表时间：
2021
影响因子：
4.6
通讯作者：
A. Masri
中科院分区：
文献类型：
--
作者：
Morris M. Kim;C. Kolseth;Dayna Carlson;A. Masri
临床心力衰竭、限制性心肌病和心律失常是淀粉样心肌病的标志性特征。与靶向治疗的进展相反，淀粉样心肌病的临床管理普遍缺乏循证实践指南。在这篇综述中，我们回顾了常规药物治疗在淀粉样心肌病中的作用，从心力衰竭管理到体位性低血压，房性心律失常，血栓栓塞并发症和预防猝死。最后，我们讨论的方法与终末期疾病的患者。
Clinical heart failure, restrictive cardiomyopathy, and arrhythmias are hallmark features of amyloid cardiomyopathy. In contrast to the advancements in targeted therapies, there is a general lack of evidence-based practice guidelines for clinical management of amyloid cardiomyopathy. In this review, we review the role of routine medical therapy in amyloid cardiomyopathy, from heart failure management to orthostatic hypotension, atrial arrhythmias, thromboembolic complications, and prevention of sudden death. We conclude by discussing approaches to patients with end-stage disease.
心脏淀粉样变性窦性心律期间发生的心房血栓：心房机电分离的证据。
影响因子：
--
作者：
Dubrey,S;Pollak,A;Skinner,M;Falk,RH
通讯作者：
Falk,RH